ICD-10 Coding for Myeloproliferative Neoplasm(D47.1, D47.1B, D47.1C)
Explore ICD-10 coding for myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia, with detailed documentation requirements.
Complete code families applicable to Myeloproliferative Neoplasm
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D47.1 | Chronic myeloproliferative disease, unspecified | Use when the specific type of myeloproliferative neoplasm is not yet determined. |
|
| D45 | Polycythemia vera | Use when polycythemia vera is confirmed by WHO criteria. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMyeloproliferative Neoplasm
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Myeloproliferative Neoplasm.
Failing to update code from D47.1 to a specific subtype
Impact
Clinical: May lead to inappropriate treatment plans., Regulatory: Non-compliance with ICD-10 coding standards., Financial: Potential loss of reimbursement for specific treatments.
Mitigation
Regularly review patient records for updated diagnostic information., Implement alerts in EHR for code updates.
Using D47.1 when a specific subtype is known
Impact
Reimbursement: May affect reimbursement rates due to lack of specificity., Compliance: Non-compliance with coding guidelines., Data Quality: Decreases accuracy of patient records.
Mitigation
Update the code to reflect the specific subtype once confirmed.
Incorrect coding of MPN subtypes
Impact
Risk of audits due to incorrect or unspecified coding of MPN subtypes.
Mitigation
Ensure thorough documentation and regular code reviews.